Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Preparation of (177Lu-DOTA)n-PAMAM-[Nimotuzumab-F(ab’)2] as a Therapeutic Radioimmunoconjugate for EGFR Overexpressed Cancers Treatment

Journal of Mathematical and Fundamental Sciences · Vol. 49 No. 3 (2017) · hlm. 258–268

DOI
10.5614/j.math.fund.sci.2017.49.3.4
ISSN
2338-5510, 2337-5760
Terbit
2017-12-13
Penerbit
Directorate for Research and Innovation (DRI) ITB
Bahasa
eng

Abstrak

Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profile and tumor penetration, and potential for eliciting host antibody responses. F(ab’)2 fragments smaller than intact monoclonal antibodies that still maintain antigen binding could solve this problem. The objective of this study was to optimize the digestion process of nimotuzumab, an anti-EGFR monoclonal antibody, into its F(ab’)2 fragment and investigate its potential as a therapeutic radioimmunoconjugate. Optimal conditions for digestion of nimotuzumab to its F(ab’)2 fragment were found to be 6 hours of digestion time with a pH of 3.5 and 1:100 mol ratio of pepsin to nimotuzumab. The purity of the F(ab’)2-nimotuzumab was confirmed by SDS-PAGE and HPLC analysis. Prior to its labeling with lutetium-177 radionuclide, the nimotuzumab-F(ab’)2 was conjugated to DOTA-PAMAM dendrimer [DOTA denotes 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, PAMAM denotes poly(amidoamine)] to form conjugate of (DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. Radiolabeling of DOTA-PAMAM-[nimotuzumab-F(ab’)2] conjugate with 177Lu resulted in (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] with radiochemical purity > 99% after purification with a PD-10 column. Further studies still need to be performed in order to confirm the potential of this radioimmunoconjugate as a radioimmunotherapeutic agent for EGFR overexpressed cancers.

Kata kunci

Jaringan kolaborasi para penulis

33 penulis · 196 tautan kepenulisan bersama · 86 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • National Nuclear Energy Agency of Indonesia
  • Padjadjaran University
  • University of Indonesia
  • Indonesian Institute of Sciences
  • Bandung Institute of Technology
  • Indonesia Defense University
  • Syarif Hidayatullah State Islamic University Jakarta
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Abdul MutalibPadjadjaran University5
Veronika Yulianti SusiloNational Nuclear Energy Agency of Indonesia4
L.B.S. KardonoIndonesian Institute of Sciences4
Arry YanuarUniversity of Indonesia4
C.N. ArdiyatnoNational Nuclear Energy Agency of Indonesia3
Sri SetiyowatiNational Nuclear Energy Agency of Indonesia3
Wening LestariNational Nuclear Energy Agency of Indonesia2
Agus AriyantoNational Nuclear Energy Agency of Indonesia2
Puji WidayatiNational Nuclear Energy Agency of Indonesia2
Sandra HermantoSyarif Hidayatullah State Islamic University Jakarta2
Yahdiana HarahapIndonesia Defense University2
Sunarhadijoso SoenarjoNational Nuclear Energy Agency of Indonesia2
Anton BahtiarUniversity of Indonesia2
D. HaffidNational Nuclear Energy Agency of Indonesia2
Setiawan SetiawanAfiliasi tidak diketahui2
Dede KurniasihNational Nuclear Energy Agency of Indonesia2
Anung PujiyantoNational Nuclear Energy Agency of Indonesia2
Mujinah MujinahNational Nuclear Energy Agency of Indonesia2
Witarti WitartiNational Nuclear Energy Agency of Indonesia2
Y. SusiloAfiliasi tidak diketahui1
Gina MondridaNational Nuclear Energy Agency of Indonesia1
Triningsih TriningsihNational Nuclear Energy Agency of Indonesia1
S. DarwatiNational Nuclear Energy Agency of Indonesia1
Muhamad Abdulkadir MartoprawiroBandung Institute of Technology1
Aisyah ElliyantiAndalas University1
Johan S. MasjhurPadjadjaran University1
Tri Hanggono AchmadPadjadjaran University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://journals.itb.ac.id/index.php/jmfs/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Preparation of (177Lu-DOTA)n-PAMAM-[Nimotuzumab-F(ab’)2] as a Therapeutic Radioimmunoconjugate for EGFR Overexpressed Cancers Treatment</dc:title>
	<dc:creator>Humani, Titis Sekar</dc:creator>
	<dc:creator>Sutari, Sutari</dc:creator>
	<dc:creator>Triningsih, Triningsih</dc:creator>
	<dc:creator>Ramli, Martalena</dc:creator>
	<dc:creator>Ritawidya, Rien</dc:creator>
	<dc:creator>Haryuni, Ratna Dini</dc:creator>
	<dc:subject xml:lang="en-US">dendrimer PAMAM</dc:subject>
	<dc:subject xml:lang="en-US">EGFR</dc:subject>
	<dc:subject xml:lang="en-US">nimotuzumab-F(ab’)2</dc:subject>
	<dc:subject xml:lang="en-US">pepsin digestion</dc:subject>
	<dc:subject xml:lang="en-US">177Lu-DOTA-PAMAM-[nimotuzumab-F(ab’)2]</dc:subject>
	<dc:description xml:lang="en-US">Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profile and tumor penetration, and potential for eliciting host antibody responses. F(ab’)2 fragments smaller than intact monoclonal antibodies that still maintain antigen binding could solve this problem. The objective of this study was to optimize the digestion process of nimotuzumab, an anti-EGFR monoclonal antibody, into its F(ab’)2 fragment and investigate its potential as a therapeutic radioimmunoconjugate. Optimal conditions for digestion of nimotuzumab to its F(ab’)2 fragment were found to be 6 hours of digestion time with a pH of 3.5 and 1:100 mol ratio of pepsin to nimotuzumab. The purity of the F(ab’)2-nimotuzumab was confirmed by SDS-PAGE and HPLC analysis. Prior to its labeling with lutetium-177 radionuclide, the nimotuzumab-F(ab’)2 was conjugated to DOTA-PAMAM dendrimer [DOTA denotes 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, PAMAM denotes poly(amidoamine)] to form conjugate of (DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. Radiolabeling of DOTA-PAMAM-[nimotuzumab-F(ab’)2] conjugate with 177Lu resulted in (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] with radiochemical purity &gt; 99% after purification with a PD-10 column. Further studies still need to be performed in order to confirm the potential of this radioimmunoconjugate as a radioimmunotherapeutic agent for EGFR overexpressed cancers.</dc:description>
	<dc:publisher xml:lang="en-US">Directorate for Research and Innovation (DRI) ITB</dc:publisher>
	<dc:date>2017-12-13</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journals.itb.ac.id/index.php/jmfs/article/view/2375</dc:identifier>
	<dc:identifier>10.5614/j.math.fund.sci.2017.49.3.4</dc:identifier>
	<dc:source xml:lang="en-US">Journal of Mathematical and Fundamental Sciences; Vol. 49 No. 3 (2017); 258-268</dc:source>
	<dc:source>2338-5510</dc:source>
	<dc:source>2337-5760</dc:source>
	<dc:source>10.5614//j.math.fund.sci.2016.49.3</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://journals.itb.ac.id/index.php/jmfs/article/view/2375/2832</dc:relation>
</oai_dc:dc>